enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$1.76−0.09 (-4.86%)
Close on Nov 19, 2026Market cap $117.95MP/E –Yield 0.00%
enGene Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
enGene Therapeutics's free cash flow for the twelve months ending Jul 31, 2026 was -$104.00M. For fiscal 2025 it was -$100.72M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$100.72M | – |
| FY2024 | Oct 31, 2024 | -$49.21M | – |
| FY2023 | Oct 31, 2023 | -$25.06M | – |
| FY2022 | Oct 31, 2022 | -$17.75M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$18.95M | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$30.60M | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$29.06M | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$25.40M | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$26.34M | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$22.99M | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$26.00M | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$19.81M | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$7.18M | – |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$14.34M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$7.88M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$6.91M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -$7.46M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$4.45M | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | -$6.24M | – |
See a number that looks wrong?